OVERSEA CHINESE BANKING Corp Ltd Takes Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 543 shares of the medical equipment provider’s stock, valued at approximately $283,000.

Other hedge funds have also recently modified their holdings of the company. Atala Financial Inc bought a new stake in shares of Intuitive Surgical during the 4th quarter valued at $25,000. Berbice Capital Management LLC purchased a new position in shares of Intuitive Surgical in the 4th quarter worth about $26,000. BankPlus Trust Department purchased a new position in shares of Intuitive Surgical in the 4th quarter worth about $28,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Intuitive Surgical in the 4th quarter worth about $31,000. Finally, Decker Retirement Planning Inc. purchased a new position in shares of Intuitive Surgical in the 4th quarter worth about $36,000. Institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ISRG shares. Bernstein Bank lifted their price target on Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th. Morgan Stanley raised Intuitive Surgical from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $522.00 to $650.00 in a research report on Monday, December 2nd. JPMorgan Chase & Co. boosted their target price on Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Erste Group Bank lowered Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research report on Monday. Finally, Raymond James boosted their price target on Intuitive Surgical from $560.00 to $688.00 and gave the company an “outperform” rating in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $611.86.

Insiders Place Their Bets

In other news, CFO Jamie Samath sold 94 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total transaction of $53,684.34. Following the sale, the chief financial officer now directly owns 2,630 shares of the company’s stock, valued at $1,502,019.30. This represents a 3.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 11,545 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $499.22, for a total value of $5,763,494.90. Following the sale, the executive vice president now directly owns 5,224 shares in the company, valued at $2,607,925.28. This trade represents a 68.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,754 shares of company stock worth $17,691,621 in the last three months. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Price Performance

ISRG stock opened at $491.81 on Friday. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00. The company has a market capitalization of $175.17 billion, a price-to-earnings ratio of 76.73, a PEG ratio of 5.85 and a beta of 1.43. The business has a 50 day simple moving average of $563.34 and a two-hundred day simple moving average of $531.34.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.